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A B S T R A C T
Background
Long-term retention of patients in Africa’s rapidly expanding antiretroviral therapy (ART)
programs for HIV/AIDS is essential for these programs’ success but has received relatively little
attention. In this paper we present a systematic review of patient retention in ART programs in
sub-Saharan Africa.
Methods and Findings
We searched Medline, other literature databases, conference abstracts, publications archives,
and the ‘‘gray literature’’ (project reports available online) between 2000 and 2007 for reports
on the proportion of adult patients retained (i.e., remaining in care and on ART) after 6 mo or
longer in sub-Saharan African, non-research ART programs, with and without donor support.
Estimated retention rates at 6, 12, and 24 mo were calculated and plotted for each program.
Retention was also estimated using Kaplan-Meier curves. In sensitivity analyses we considered
best-case, worst-case, and midpoint scenarios for retention at 2 y; the best-case scenario
assumed no further attrition beyond that reported, while the worst-case scenario assumed that
attrition would continue in a linear fashion. We reviewed 32 publications reporting on 33
patient cohorts (74,192 patients, 13 countries). For all studies, the weighted average follow-up
period reported was 9.9 mo, after which 77.5% of patients were retained. Loss to follow-up and
death accounted for 56% and 40% of attrition, respectively. Weighted mean retention rates as
reported were 79.1%, 75.0% and 61.6 % at 6, 12, and 24 mo, respectively. Of those reporting 24
mo of follow-up, the best program retained 85% of patients and the worst retained 46%.
Attrition was higher in studies with shorter reporting periods, leading to monthly weighted
mean attrition rates of 3.3%/mo, 1.9%/mo, and 1.6%/month for studies reporting to 6, 12, and
24 months, respectively, and suggesting that overall patient retention may be overestimated in
the published reports. In sensitivity analyses, estimated retention rates ranged from 24% in the
worse case to 77% in the best case at the end of 2 y, with a plausible midpoint scenario of 50%.
Conclusions
Since the inception of large-scale ART access early in this decade, ART programs in Africa
have retained about 60% of their patients at the end of 2 y. Loss to follow-up is the major cause
of attrition, followed by death. Better patient tracing procedures, better understanding of loss
to follow-up, and earlier initiation of ART to reduce mortality are needed if retention is to be
improved. Retention varies widely across programs, and programs that have achieved higher
retention rates can serve as models for future improvements.
The Editors’ Summary of this article follows the references.
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Introduction
In the half decade since the first large-scale antiretroviral
treatment (ART) programs for HIV/AIDS were launched in
sub-Saharan Africa, much attention has focused on patients’
day-to-day adherence to antiretroviral (ARV) medications [1–
3]. Long-term retention of patients in treatment programs, a
prerequisite for achieving any adherence at all, has received
far less attention. Perhaps because most large scale treatment
providers have few resources available to track missing
patients, most studies treat patient attrition as a side issue
and focus solely on describing those patients who are
retained. Moreover, adherence can be assessed over very
short periods, whereas long-term retention requires, by
definition, long-standing programs.
Attrition from antiretroviral treatment programs is gen-
erally divided into four categories. The two most common are
(1) the death of the patient—several studies have reported
high rates of early mortality—and (2) ‘‘loss to follow-up,’’ a
catch-all category for patients who miss scheduled clinic visits
or medication pickups for a specified period of time. Some
patients remain in care but stop taking ARV medications (3).
Others transfer to other facilities and continue on ART (4).
Treatment discontinuation raises some of the same
concerns about drug resistance that incomplete adherence
does and, even worse, negates much of the benefit sought by
those implementing treatment programs. Patients with
clinical AIDS who discontinue ART will likely die within a
relatively short time [4]. High rates of attrition from treat-
ment programs thus pose a serious challenge to program
implementers and constitute an inefficient use of scarce
treatment resources. In this study, we analyzed reported
treatment program retention and attrition in sub-Saharan
Africa in order to document the magnitude of the problem
and help policy makers and program managers address the
challenge of patient retention.
Methods
Definitions
For this review, ‘‘retention’’ refers to patients known to be
alive and receiving highly active ART at the end of a follow-
up period. ‘‘Attrition’’ is defined as discontinuation of ART
for any reason, including death, loss to follow-up, and
stopping ARV medications while remaining in care. Transfer
to another ART facility, where reported, is not regarded as
attrition—patients who transfer are assumed to be retained.
We accepted the varying definitions of loss to follow-up used
by the respective studies. Many studies considered patients
lost if they were more than 3 mo late for a scheduled
consultation or medication pickup, but some studies used
more or less stringent definitions ranging from 1 to 6 mo late
for a scheduled consultation or medication pick-up.
Inclusion and Exclusion Criteria
Studies were included in the review if they reported the
proportion of adult HIV-1 patients retained in highly active
ART programs implemented in service delivery (nonresearch)
settings in sub-Saharan Africa. All patients who initiated ART
had to be included in the report, not just those still in care at
the time of censoring (i.e., only intention-to-treat analyses
were included). Clinical trials, including Phase 3 trials, were
excluded, although some subjects of reviewed studies trans-
ferred into the treatment program from a clinical trial. A
median follow-up period of at least six full months (26 weeks)
was also required. Studies that reported mortality but not
other categories of attrition and studies that reported only
on-treatment analyses, or where we were unable to determine
whether the study was intention-to-treat or not, were also
excluded. A few of the reviewed studies did not differentiate
between adult and pediatric patients; those that considered
only pediatric patients were excluded.
Search Strategy
To identify eligible studies, we conducted a systematic
search of the English-language published literature, gray
literature (project reports available online), and conference
abstracts between 2000 and 2007. The search included Ovid
Medline (1996 to July 2007), EMBASE (inception to July 2007),
ISI Web of Science (August 2002 to July 2007), the Cumulative
Index to Nursing & Allied Health Literature (2002 to July
2007), and the Cochrane Database of Systematic Reviews
(inception to second quarter 2007). We also searched the
abstracts of the conferences of the International AIDS
Society (inception to 2006), the Conference on Retroviruses
and Opportunistic Infections (inception to 2007), the HIV
Implementers’ Meetings (2006–2007), and the South African
AIDS Conference (2005–2007). The bibliographies of five
recently published reviews of treatment outcomes, mortality,
or ARV adherence in resource-constrained settings were also
searched [1–3,5,6]. Our search strategy combined the terms
‘‘antiretroviral’’ and ‘‘Africa’’ or ‘‘developing countries’’ with
each of retention/attrition/loss to follow-up/mortality/evalua-
tion/efficacy. When more than one source reported on the
same cohort of patients, the source containing the most
detailed data about retention and attrition or the longest
follow-up period was selected for the review. Although non-
English databases were not searched, English-language
abstracts of non-English papers identified in our search were
included. Eligible studies were identified by the first author
(SR) and eligibility confirmed by the other authors (MF and
CG).
It should be noted that the Antiretroviral Therapy in Low
Income Countries (ART-LINC) collaboration has recently
reported aggregate 1 y mortality and loss to follow-up rates
for 13 cohorts in sub-Saharan Africa [5]. Some of the patients
in these cohorts are included in the studies reviewed here. To
avoid duplication, findings from the ART-LINC cohorts were
not included in this analysis but are noted in the discussion.
Data Analysis
Most studies reported patient attrition at months 6, 12,
and/or 24 after treatment initiation. We therefore used these
same intervals in this analysis. For papers that reported on
intervals other than 6, 12, or 24 mo, we classified the reported
attrition rate using the nearest time point. If the report did
not list attrition rates by time, but did list a median duration
of observation, we estimated attrition at the 6, 12, or 24 mo
interval closest to the reported observation period. In some
cases, follow-up periods and/or retention rates were calcu-
lated by the authors using data provided in the article or
extracted from figures (e.g. Kaplan-Meier survival curves).
Where appropriate, we calculated weighted averages for
demographic features of the cohort participants or other
factors related to the studies. For proportions, averages were
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weighted by the inverse of their variances [1 4 (p3 [1 p] 4
n), where p is the proportion and n is the sample size]. Because
we did not have the individual patient data for continuous
variables nor their standard deviations, we were unable to
calculate variances for these variables. In these situations, we
weighted by cohort size.
In some instances, studies reported follow-up to 12 or 24
mo but did not report on intermediate retention rates. In
plotting attrition for such studies over time we used
extrapolated values, taking the midpoint between the known
adjacent values. For example, if a study reported to 12 mo but
did not report the 6 mo value, we defined the 6 mo value as
the midpoint between 0 and 12 mo, with 100% at baseline
representing all of those who initially started therapy. We
calculated weighted average attrition rates at each interval (6,
12, and 24 mo) for the reported numbers of participants
remaining when using reported values and for the estimated
numbers of participants remaining when using extrapolated
values. Selected demographic variables relating cohort or
program characteristics to attrition rates were analyzed using
linear regression. Because only a few studies reported beyond
24 mo, we were unable to calculate any meaningful summary
statistics beyond the 24 mo mark.
To estimate aggregate average attrition rates at 6, 12, and
24 mo we used several approaches. Attrition for each
program was plotted separately and attrition rates calculated
as the percentage of patients lost per month. We also plotted
Kaplan-Meier survival curves using the 6, 12, and 24 mo
intervals as the step-down points. Fewer studies presented 12
mo data than 6 mo data, however, and fewer still contained 24
mo data. Many of the studies with the highest attrition
contributed data only for the shorter time intervals. Given
the concern that shorter durations of reporting could be
associated with lower rates of patient retention, we also
conducted sensitivity analyses to model possible future
retention. For the best-case scenario, we optimistically
assumed that no further attrition would occur beyond the
last reported observation and extrapolated the last reported
retention value forward to 24 mo. In the worst-case scenario,
we extrapolated the slope of attrition forward in time,
assuming that each cohort’s attrition would continue along
the same slope from the last reported observation to month
24. We assigned a lower limit of 0% in those situations where
the estimated future retention rate fell below 0%. Our
midpoint scenario was the mean of the best- and worst-case
scenarios. Analyses were conducted using Excel, SAS version
8.2, and SPSS version 11.0.
Results
We included 32 publications reporting on 33 patient
cohorts totaling 74,289 patients in 13 countries in our
analysis. These studies were selected from a total of 871
potentially relevant, unique citations identified in our search
(Figure 1).
Table 1 summarizes key features of the studies, including
the sites at which they were conducted. Not all of the
publications reported all the details we sought about program
and patient characteristics and retention, but all provided at
least one indicator of patient retention after a median follow-
up period of at least 6 mo. The studies report on patients who
initiated ART as early as 1996, though most enrolled their
cohorts between 2001 and 2004. The studies were published
or presented between 2002 and 2007, with the majority
appearing as peer reviewed articles in 2006 or 2007. Most of
the programs were implemented by the public sector (17 of
33, 52%). Of 33 cohorts, 15 (45%) fully subsidized the cost of
ART; six (18%) were partially subsidized; and six (18%)
required patients to pay fully for their care; the rest did not
report their payment structure. Roughly half were single-site
programs (15 of 33, 45%); multi-site programs contributed
data from between two and 69 sites.
Table 1 also provides the population characteristics of the
cohorts studied. The weighted mean age of the cohort
participants was 35.5 y, and 53.7% of all patients were female
(range 6%–70%). All but one cohort had median starting
CD4þ T cell counts at or well below 2003 103 cells/mm3, with
a weighted mean starting CD4þT cell count of 1323103 cells/
mm3 (range 43–204).
Table 2 presents the proportion of patients from each
cohort who remained alive and under treatment with
antiretroviral medications, transferred to another treatment
facility, died, were lost to follow-up, or discontinued treat-
ment with ARVs but remained in care at the end of the
median follow-up period. Bearing in mind that we excluded
studies with less than 6 mo median follow-up, the weighted
average follow-up was 9.9 mo, after which time overall
retention of patients alive, in care, and on ART was 77.5%.
Across all the cohorts, the largest contributor to attrition
was loss to follow-up (56% of attrition), followed by death
(40% of attrition). The widely varying definitions of loss to
follow-up used by the studies are indicated in Table 2. A small
fraction (4% of attrition) discontinued ART but remained
under care at the same site.
Table 3 reports overall retention at 6, 12, and 24 mo. SA 1
had the highest retention at 12 mo. While this program did
not report for 6 mo, at 12 mo its retention of 90% was still
higher than the highest reported value among the programs
Figure 1. Study Flow Chart
doi:10.1371/journal.pmed.0040298.g001
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that reported their 6 mo outcomes. The programs with the
lowest retention at each time point were Malawi 4 (55%) at 6
mo; Uganda 2 (49%) at 12 mo; and Uganda 1 (46%) at 24 mo.
Malawi 4 did not report beyond 6 mo and Uganda 2 did not
report beyond 12 mo, but were both on a trajectory toward
even lower retention rates at the later time points.
Using linear regression, we found no association between 6
mo attrition rates and cohort size (p ¼ 0.32), attrition and
baseline CD4þ cell counts (p¼ 0.72), proportion of women (p
¼0.23), or year of program initiation (p¼0.40). Programs that
required no payment had higher retention rates at 6 mo
compared to those requiring partial or full payment (86.5%
versus 76.7%, p ¼ 0.01).
Figures 2A–2C plot attrition rates for each cohort
separately. The studies are clustered on the basis of duration
of reporting. By 6 mo, 9 of 33 cohorts (27%) had 20% or
greater attrition rates; by 12 mo this proportion had risen to
16 of 25 reporting cohorts (64%).
The weighted mean retention rates as reported in the
studies were 79.8% at 6 mo, 75.1% at 12 mo, and 61.6% at 24
mo. As an alternative approach, we also plotted Kaplan-Meier
survival curves at months 6, 12, and 24 for all the studies
Table 1. Characteristics of Antiretroviral Treatment Programs and Patient Cohorts Included in This Analysis (extended on next page)
Study
Code
Reference Year Report
Type
Country (City or District) Facilities
(n)
Sector
Botswana 1a Wester [21] 2005 Journal Botswana (Gaborone) 1 Public
Botswana 2a Bisson [22] 2007 Abstract Botswana (Gaborone) 1 Public
Botswana 3 Bisson [23] 2006 Journal Botswana (Gaborone) 1 Private
Cameroon 1 Laurent [24] 2005 Journal Cameroon (Douala) 19 Public and private
Cameroon 2 Guiard-Schmid [25] 2004 Abstract Cameroon (Edea) 1 Workplace
Cameroon 3 Mosoko [26] 2007 Abstract Cameroon (Limbe) 1 Public
Cameroon 4 Kenfak [27] 2006 Abstract Cameroon (unspecified) — —
Cote d’Ivoire 1 Djomand [28] 2003 Journal Cote d’Ivoire (Abidjan) 6 Public and private
Kenya 1 Macharia [29] 2003 Journal Kenya (Nairobi) 5 Private
Kenya 2 Wools-Kaloustian [30] 2006 Journal Kenya (Western Province) 8 Public
Kenya 3 Carillo de Casas [31] 2006 Abstract Kenya (Busia) — Nongovernmental
Kenya 4 Marston [32] 2007 Journal Kenya (Kibera) 1 Nongovernmental
Kenya 5 Karcher [33] 2007 Journal Kenya (Migori) 1 Public
Kenya 6 Hawkins [34] 2007 Journal Kenya (Nairobi) 1 Nongovernmental
Malawi 1f Ferradini [35] 2006 Journal Malawi (Chiradzulu District) 1 Public
Malawi 2f Libamba [36] 2006 Journal Malawi (multiple locations) 24 Public
Malawi 3f Hosseinipour [37] 2006 Abstract Malawi (Lilongwe) 1 Public
Malawi 4f Hosseinipour [10] 2006 Abstract Malawi (Lilongwe) 1 Public
Malawi 5f Zachariah [38] 2007 Journal Malawi (Thyolo) — Public
Mozambique 1 Palombi [39] 2004 Abstract Mozambique (Maputo) 1 Public
Senegal 1 Etard [40] 2006 Journal Senegal (Dakar) Unclear Public
South Africa 1 Bekker [41] 2006 Journal South Africa (Guguletu) 1 Public
South Africa 2 Charalambous [42] 2007 Journal South Africa (multiple locations) 69 Workplace
South Africa 3 Coetzee [43] 2004 Journal South Africa (Khayelitsha) 3 Public
South Africa 4 Nachega [44] 2006 Journal South Africa (multiple locations) ‘‘Many’’ Workplace
South Africa 5i Reuter [45] 2006 Journal South Africa (Lusikisiki) 1 Public
South Africa 6i Reuter [45] 2006 Journal South Africa (Lusikisiki) 12 Public
Uganda 1j Kabugo [46] 2005 Journal Uganda (Kampala) 1 Nongovernmental
Uganda 2j Weidle [47] 2002 Journal Uganda (Kampala) 3 Public and
nongovernmental
Uganda 3 Rigon [48] 2006 Abstract Uganda (northern) 2 —
Zambia 1 Stringer [11] 2006 Journal Zambia (Lusaka) 18 Public
Multi 1 Sow [49] 2006 Journal Senegal, Cote d’Ivoire, Uganda, Kenya (capital cities) 4 Unclear
Multi 2 El-Sadr [50] 2006 Abstract Kenya, Mozambique, Rwanda, South Africa, Tanzania, Ethiopia 56 Public
Total or weighted average
‘‘—’’ indicates information not reported in study.
aBotswana 1 and Botswana 2 report on the same site but different cohorts of patients.
bPeriod during which study participants initiated ART; follow-up extends beyond dates shown.
cOnly ARV-naı¨ve patients included.
dValue is for subset of study sample or for larger patient population.
eMean value, not median.
fMalawi 2 cohort may include some or all of the patients followed in Malawi 1, 3, 4, and 5.
gEstimated from data provided.
hWeighted average of median CD4þ cell counts for three annual cohorts included in study.
iSouth Africa 5 and 6 reported on the same program but different models of treatment delivery (South Africa 5 included a hospital; South Africa 6 included primary care clinics).
jUganda 1 cohort includes one site and some patients from Uganda 2.
kIncludes pediatric patients.
lWeighted by inverse of variance.
AMPATH, the Academic Model for Prevention and Treatment of HIV; AMREF, African Medical Research Foundation; DOH, Department of Health; DREAM, Drug Resources Enhancement
against AIDS and Malnutrition; ICAP, International Center for AIDS Care and Treatment Programs; MOH, Ministry of Health; MSF, Medecins Sans Frontieres; UNAIDS, The Joint United
Nations Programme on HIV/AIDS.
doi:10.1371/journal.pmed.0040298.t001
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combined. The largest fall-off occurred between 6 and 12 mo;
overall retention was approximately 89% by 6 mo, 70% by 1
year, and just under 60% by 2 years.
Four of the eight studies in Figure 2A with attrition of at
least 20% at 6 mo included data only to 6 mo. Similarly, of the
cohorts with data at 12 mo and attrition of 25% or more, six
of 11 did not extend beyond 12 mo. We therefore calculated
the slopes for attrition rates for each group of cohorts in
Figure 2A–2C separately, to determine if the average monthly
attrition rates differed as the duration of reporting increased.
As shown in Figure 2D, the weighted mean attrition rates
were 3.3%/month, 1.9%/month, and 1.6%/month for studies
reporting to 6 mo, 12 mo, and 24 mo, respectively, raising the
possibility that shorter durations of reporting were associated
with lower retention rates.
Given this apparent reporting bias, we were concerned that
reporting average retention rates using the simple aggregate
weighted averages reported above would overestimate actual
retention. We therefore conducted sensitivity analyses to
model attrition rates under three different scenarios. As
shown in Figure 3, all three scenarios are the same at 6 mo,
with approximately 80% retention. Under the best-case
scenario, further attrition would be negligible, with more
than 76% still retained by the end of 2 y. Under the worst-
case scenario, 76% of patients would be lost by 2 y. The
midpoint scenario predicted patient retention of 50% by 2 y.
Discussion
The analysis presented here suggests that ART programs in
Africa are retaining, on average, roughly 80% of their
patients after 6 mo on ART and between one-fourth and
three-fourths of their patients by the end of 2 y, depending
on the estimating method used. Prior to the availability of
ART in Africa, the median interval from HIV infection to
AIDS-related death was under 10 y; once a patient was
diagnosed with AIDS, median survival was less than 1 y [7].
Since most patients in Africa initiate ART only after an AIDS
diagnosis, most ART patients would have died within a year
had antiretroviral therapy not been available. Each patient
who is retained in care and on ART can thus be regarded as a
life saved and a source of tremendous benefit to patients’
families and communities.
For those who have struggled to launch and expand
treatment programs in resource-constrained settings, reach-
ing a 60% patient retention—and thus survival—rate after
two years of treatment, as estimated by the Kaplan-Meier
survival analysis, in just a few years’ time is an extraordinary
Table 1. Extended.
Provider Payment by
Patient Required?
Dates of Patient
Observation
Patients
Started
on ART (n)
Median Age
(Years)
Female
(%)
Median Starting
CD4þ Cell Count
(Cells/mm3)
Botswana MOH No Apr 2001–Jan 2002b 153 36 59% 96
Botswana MOH No Unclear 410 — — —
Private clinicians Full Dec 1999–Jan 2004b 346 37 58% 100
Consortium of public and private clinicians Full Oct 2000–Dec 2003 788 39 52% 123
Alucam (company) No — 26 41 50% 204
Cameroon MOH Full Feb 2002–Dec 2005 2,920 35 62% 107
— — April 2003–Dec 2004 466 — — —
UNAIDS/ Cote d’Ivoire MOH Partial Aug 1998–Aug 2000 547c 35d 50%d 182d
Private clinicians Full Oct 1996–June 2001 300 — 40% 80
AMPATH Program Partial Nov 2001–Feb 2005 2,059 37 61% 86
MSF No Jun 2003–Jul 2005 1,288 — 69% —
AMREF/ Kenya MOH No Feb 2003–Feb 2005 283 36e 70% 157
Kenya MOH No Apr 2004–Sep 2005 124 31 71% 189
— — Sep 2004–Aug 2006b 1,286 36 59% 121
MSF No 1997–Apr 2004 1,308 35 64% 112
Malawi MOH Partial 2001–Dec 2004 13,183g — 60% —
Malawi MOH Partial Jan 2003–Jul 2003b 141 39 52% 50
Malawi MOH Full Oct 2001–Apr 2002 625 38 49% 70
Malawi MOH and MSF — Apr 2003–Apr 2005 1,634 — 65% —
DREAM Program No — 401g — 64%d —
Senegal MOH Partial Aug 1998–Sep 2005 404 37 55% 128
Western Cape Province DOH No Oct 2002–Sep 2005 1,139 — 69% 128h
Anglo American (company) No Oct 2002–Dec 2005 2,262 41 5% 158
MSF and Western Cape Province DOH No May 2001–Jul 2003 287c 31 70% 43
Aid for AIDS disease management program No Jan 1999–Sep 2004 7,080 37d 61%d 149d
MSF and Eastern Cape Province DOH No Oct 2005–Sep 2005 430 — — —
MSF and Eastern Cape Province DOH No Oct 2005-Sep 2005 595 — — —
Uganda MOH and UNAIDS Partial Aug 1998–Dec 2002 321 38 49% 79
Uganda MOH and UNAIDS Full Aug 1998–Jul 2000 399 37k 48% 73g
— — Jun–Jul 2005b 105 — — 154
Zambia MOH and partners No Apr 2004–Nov 2005 16,198 35 61% 143e
CARE Program No — 206 36 62% 119
ICAP Program Unclear Feb 2004–Sep 2005b 16,575k — 64% —
74,289 35.5l 53.7%l 132l
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accomplishment. It is also noteworthy in the global context:
in developed countries, adherence to medication for chronic
diseases in general averages only 50% [8]. Similarly, treatment
completion rates for tuberculosis, which requires a tempo-
rary rather than permanent commitment to adherence and a
less demanding dosing schedule, average 74% in the African
region, with a range among countries from 22% to 94% [9].
Taken in the context of medication adherence in general, the
record of African ART programs lies within the bounds of
previous experience.
At the same time, however, losing up to half of those who
initiate ART within two years is cause for concern. From the
data as reported, attrition averaged roughly 22% at 10 mo of
follow-up. This average comprised mainly deaths (40% of
attrition) and losses to follow-up (56%). In comparison, the
ART-LINC Collaboration, which analyzed data from 18
cohorts across the developing world, reported loss to
follow-up rates among the 13 sub-Saharan African cohorts
averaging 15% (range 0%–44%) in the first year after
initiation; mortality averaged 4.2% across all 18 cohorts
(African regional rate not provided) [5].
On the basis of our survival and sensitivity analyses, we
believe that actual attrition is higher than the 22% average we
report, mainly because the programs with the highest
attrition were least likely to provide data beyond the first 6
mo of ART. There are several plausible explanations for the
higher attrition seen among programs with shorter durations
of reporting. One possibility is that limited availability of
Table 2. Median Follow-Up and Rates of Patient Attrition, as Reported, from Antiretroviral Treatment Programs
Study Code Median
Follow-Up
(Months)
Died (A) Lost to
Follow-Up
(B)
Stopped
ARVs (C)
Total Attrition
from ART (D)a
Total
Retained (E)a
Transferred
Care (F)
Total Retained
at Original
Site (G)a
Botswana 1 22.2 15.7% 8.4%b — 24.1% 75.9% 5.2%c 70.7%
Botswana 2 10.2 16.8% 5.4% — 22.2% 77.8% — 77.8%
Botswana 3 12 5.2% 12.4%d — 17.6% 82.4% 12.1% 70.3%
Cameroon 1 13 6.6% 25.1%e — 31.7% 68.3% — 68.3%
Cameroon 2 11.1 7.7% 38.5% — 46.2% 53.8% — 53.8%
Cameroon 3 6.2 — — — — — — —
Cameroon 4 18 1.9% 25.5% — 27.5% 72.5% — 72.5%
Cote d’Ivoire 1 — — —e — — — — —
Kenya 1 — 11.3% 19.0% 7.7% 38.0% 62.0% 9.0% 53.0%
Kenya 2 9.2 5.4% 24.5%e — 29.9% 70.1% — 70.1%
Kenya 3 11 9.9% 7.0% — 16.9% 83.1% — 83.1%
Kenya 4 7.1 4.2% 8.8% 1.8% 14.8% 85.2% 0.7% 84.5%
Kenya 5 9 12.1% 15.3%f — 27.4% 72.6% — 72.6%
Kenya 6 11.7 1.1% 34.8%e — 35.9% 64.1% 4.9% 59.2%
Malawi 1 8.3 18.6% 7.0%g 0.5% 26.1% 73.9% — 73.9%
Malawi 2 6 7.8% 7.9% 0.8% 16.5% 83.5% 1.9% 81.6%
Malawi 3 6 27.7% 7.8% 2.8% 38.3% 61.7% — 61.7%
Malawi 4 6.2 7.0%h 33.6% 4.0% 44.6% 55.4% — 55.4%
Malawi 5 6.3i 8.9% 2.4%e 2.0% 13.3% 86.7% — 86.7%
Mozambique 1 9.5 12.5% 9.3% — 21.8% 78.2% — 78.2%
Senegal 1 46.0 23.0% 4.0%j — 27.0% 73.0% — 73.0%
South Africa 1 12.3i 6.8% 2.9% — 9.7% 90.3% 10.5% 79.7%
South Africa 2 18.7i 5.0% 25.1% — 30.1% 69.9% — 69.9%
South Africa 3 13.9 13.2% 0.3%e 3.0% 16.5% 83.5% 1.0% 82.5%
South Africa 4 19.5i 5.4% 25.4% — 30.8% 69.2% — 69.2%
South Africa 5 12.0 13.5% 19.3% — 32.8% 67.2% 4.0% 63.2%
South Africa 6 12.0 16.8% 2.2% — 19.0% 81.0% 4.9% 76.1%
Uganda 1 16.8 21.5% 39.3% — 60.8% 39.2% — 39.2%
Uganda 2 3.3i 16.0% 24.0% 3.0% 43.0% 57.0% 9.0% 48.0%
Uganda 3 6.0 14.3% 4.8% — 19.0% 81.0% — 81.0%
Zambia 1 6.8 7.1% 21.0%k 0.4% 28.5% 71.5% — 71.5%
Multi 1 22.2 7.8% 6.3%e 3.9% 18.0% 82.0% — 82.0%
Multi 2 7.0i 8.0% 7.0% 4.7% 19.7% 80.3% 0.3% 80.0%
Weighted averages 9.9l — — — — 77.5%m — —
‘‘—’’ indicates that these data could not be determined from the report.
aCalculations: D¼ 1  (A þ B þ C); E ¼ 1  D; G ¼ E  F.
bLost to follow-up (LTFU) defined as missing two consecutive clinic visits.
cTransfer rate after 1 y (rate at median follow-up not reported).
dLTFU defined as having no viral load results after treatment initiation.
eLTFU defined as . 3 mo late for a visit or medication pickup or no visit in past 3 mo.
fLTFU defined as . 4 mo late for a visit or medication pickup.
gLTFU defined as . 2 mo late for a visit or medication pickup.
hLTFU defined as missing two consecutive clinic visits or no visit in past 3 mo.
iMedian not reported; table shows mean follow-up instead.
jLTFU defined as . 6 mo late for a visit or medication pickup.
kLTFU defined as . 1 mo late for a visit or medication pickup.
lWeighted by cohort size.
mWeighted average of the totals retained; weighted by inverse of variance.
doi:10.1371/journal.pmed.0040298.t002
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resources to a given program could affect both its ability to
retain patients and to conduct long-term surveillance of its
outcomes. Another, less pessimistic explanation is that
shorter durations of reporting reflect newer programs that
are still in the process of developing optimal strategies for
patient retention: had they reported at a later point in their
implementation, retention rates might have been higher. The
magnitude of the under-reporting bias is also uncertain,
although our sensitivity analysis gives a plausible range
between two implausible extremes (the best case being
implausible because it assumes zero further attrition beyond
Table 3. Retention of Patients at 6, 12, and 24 Months after
Initiation of ART
Study
Code
Percentage of
Patients Retained at:
Notes
6 mo 12 mo 24 mo
Botswana 1 — 76.3% 75.9% 24 mo value is at 22.2 mo
Botswana 2 — 77.8% — 12 mo value is at 10.2 mo
Botswana 3 — 82.4% —
Cameroon 1 85.0% 76.0% 62.0% Values estimated from graph
Cameroon 2 — 50.0% — 12 mo value is at 11.1 mo
Cameroon 3 66.0% 58.0% 47.0%
Cameroon 4 — — 72.5% 24 mo value is at 18 mo
Cote d’Ivoire 1 76.0% 62.0% — Values exclude non-naı¨ve
patients
Kenya 1 86.0% 78.0% 66.0%
Kenya 2 — 70.1% — 12 mo value is at 9.2 mo
Kenya 3 — 81.4% — Value based on survival analysis
in source
Kenya 4 88.0% 81.0% — Values based on survival analysis
in source
Kenya 5 — 67.4% — Value based on survival analysis
in source
Kenya 6 — 64.1% —
Malawi 1 78.0% 76.0% 66.0% Values estimated from graph,
include patients who stopped
ARVs
Malawi 2 83.5% — —
Malawi 3 61.7% — —
Malawi 4 55.4% — — 6 mo value is at 6.1 mo
Malawi 5 86.7% — —
Mozambique 1 — 78.2% — 12 mo value is at 9.5 mo
South Africa 1 — 90.3% — Value estimated from graph
South Africa 2 — 77.1% —
South Africa 3 88.2% 86.7% 85.4%
South Africa 4 86.1% — —
South Africa 5 — 67.2% —
South Africa 6 — 81.2% —
Senegal 1 — 86.6% 79.0%
Uganda 1 — 56.0% 46.0%
Uganda 2 63.0% 49.0% —
Uganda 3 81.0% — —
Zambia 1 71.6% — — 6 mo value is at 6.8 mo
Multi 1 — — 80.6% 24 mo value is at 22.2 mo
Multi 2 80.3% — — 6 mo value is at 7 mo
doi:10.1371/journal.pmed.0040298.t003
Figure 2. Attrition Rates by Reporting Duration
(A) Studies reporting to 6 mo median follow-up.
(B) Studies reporting to 12 mo median follow-up.
(C) Studies reporting to 24 mo median follow-up.
(D) Weighted mean attrition rates by duration cohort.
SA, South Africa.
doi:10.1371/journal.pmed.0040298.g002
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the point of last reporting, and the worst case because it
assumes that there will be constant attrition over time, rather
than reaching a plateau or at least slowing substantially). The
midpoint scenario suggests that approximately half of all
patients started on ART were no longer on treatment at the
end of two years.
One of the principal challenges to this analysis is
interpreting the large proportion of attrition from ‘‘loss to
follow-up.’’ Some of these patients undoubtedly represent
unrecorded deaths, but others may be patients who identified
alternative sources for ART or had taken an extended
‘‘break’’ from therapy, to which they will return when their
condition worsens again or they obtain the financial
resources needed for transport or clinic fees. One study in
Malawi discovered, for example, that 24% of patients
originally recorded as lost to follow-up re-enrolled at the
same site two years later when ART became free of charge
[10]. For some of the studies included in this analysis, on the
other hand, the unrecorded death explanation is more
persuasive. For example, the Zambia 1 cohort of more than
16,000 patients reported 21% loss to follow-up after
approximately 6 mo [11]. The scope and scale of this program
means that it is the primary source of ART in Lusaka, making
it unlikely that most of the estimated 3,300 lost patients could
have found alternative sources of care. A recent attempt to
trace lost-to-follow-up patients in Malawi determined that
50% had died, 27% could not be found, and most of the rest
had stopped ART [12].
Because those reporting on these cohorts do not know
what ultimately happened to patients categorized as lost to
follow-up, high loss to follow-up rates can have varied
interpretations. A good deal of research on barriers to
adherence and reasons for treatment discontinuation has
been published [13]. Important barriers to adherence include
cost of drugs and/or transport, fear of disclosure or stigma,
and side effects [14,15]. Some of these barriers can be
addressed relatively easily, for example by providing trans-
port vouchers to ensure that patients can attend the clinic;
others, such as stigma, require more profound changes. In
any case, high reported rates of loss to follow-up are a strong
call to improve patient tracing procedures, to minimize the
number of patients who fall into the difficult-to-address
category of ‘‘lost, reason unknown.’’
Given that the long-term prognosis of ART patients is
inversely related to starting CD4þ T cell counts [16,17], an
additional issue to consider is the low median starting CD4þ
cell counts reported by every one of the studies in this
analysis. This problem has been identified previously,
particularly in South Africa [18–20]. The analysis here makes
clear that the problem is nearly universal in Africa and cuts
across all types of treatment programs. It is evident in the
high death rates reported by some studies after only a few
months of follow-up, such as Malawi 3.
There is a high degree of heterogeneity in retention rates
between the different cohorts in our analysis and among
categories of attrition. Some programs appear to have been
highly successful in retaining patients, while others clearly
struggled to do so. Some programs have suffered high
mortality rates but low loss to follow-up, others the opposite.
Early mortality, which may be largely due to the late stage at
which many patients present for treatment, requires inter-
ventions different from those needed to address later loss to
follow-up, about which very little is known. Interventions to
address the various types of attrition must thus be tailored to
local circumstances. The success of some programs with very
high retention may provide examples that others can follow.
The findings here can thus be seen as a part of an ongoing
process to identify and solve problems within existing
treatment programs, even as we expand their scope and
launch new ones.
Our analysis has a number of limitations, chiefly that
incomplete reporting forced us to extrapolate some values.
Extrapolating backward assumes that attrition rates are
distributed linearly over time, which is unlikely to be the
case. Evidence from this and other studies suggest that the
highest attrition occurs during the first 6 mo. However, this
Figure 3. Sensitivity Analysis for Attrition
doi:10.1371/journal.pmed.0040298.g003
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limitation only pertains to the shape of the attrition curves,
not to their final end points. Extrapolating forward, which we
used only in the sensitivity analysis to establish the hypo-
thetical ‘‘worst case’’ scenario, also suffers from this limi-
tation, compounded by the fact that our confidence in the
forward boundary is limited.
In addition, our analysis is necessarily limited to publicly
available reports and thus potentially subject to publication
bias. Researchers may be less inclined to publish long-term
outcomes from cohorts that have experienced very high early
attrition. It is also likely that programs with better access to
resources, both financial and human, are also better able to
monitor, analyze, and publish their results. Our aggregate
findings may thus represent the better-resourced programs in
Africa.
In conclusion, African ART programs are retaining about
60% of their patients in the first two years. This average
masks a great deal of heterogeneity, however. At one end of
the spectrum represented by the reviewed studies, two-year
retention neared 90%; at the other end, attrition reached
50%. Better information on those who are lost to follow-up is
urgently needed. Since losses to follow-up account for the
majority of all attrition in more than half of the studies
reviewed, the problem of attrition cannot be addressed
effectively without better means to track patients. Only then
can we address the pressing question of why patients drop out
and what conditions, assistance, or incentives will be needed
to retain them.
Supporting Information
Protocol S1. Search Protocol
Found at doi:10.1371/journal.pmed.0040298.sd001 (85 KB DOC).
Acknowledgments
We thank several colleagues who read and commented on the
manuscript prior to publication. The opinions expressed herein are
those of the authors and do not necessarily reflect the views of the
funders or those colleagues.
Author contributions. All authors contributed to developing the
ideas presented in this paper, analyzing the data, and editing the
manuscript.
References
1. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006)
Adherence to antiretroviral therapy in sub-Saharan Africa and North
America: a meta-analysis. JAMA 296: 679–690.
2. Akileswaran C, Lurie MN, Flanigan TP, Mayer KH (2005) Lessons learned
from use of highly active antiretroviral therapy in Africa. Clin Infect Dis 41:
376–385.
3. Gill CJ, Hamer D, Simon JL, Thea DM, Sabin L (2005) No room for
complacency about adherence to antiretroviral therapy in sub-Saharan
Africa. AIDS 19: 1243–1249.
4. Mocroft AJ, Lundgren JD, d’Armino MA, Ledergerber B, Barton SE, et al.
(1997) Survival of AIDS patients according to type of AIDS-defining event.
Int J Epidemiol 26: 400–407.
5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006)
Mortality of HIV-1-infected patients in the first year of antiretroviral
therapy: comparison between low-income and high-income countries.
Lancet 367: 817–824.
6. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy
programs in resource-poor settings: a meta-analysis of the published
literature. Clin Infect Dis 41: 217–224.
7. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, et al. (2002) HIV-1
infection in rural Africa: is there a difference in median time to AIDS and
survival compared with that in industrialized countries? AIDS 16: 597–603.
8. Sabate E (2003) Adherence to long-term therapies: evidence for action.
Geneva: World Health Organization. Available: http://www.who.int/entity/
chp/knowledge/publications/adherence_introduction.pdf. Accessed 25 July
2007.
9. World Health Organization (2007) Global tuberculosis control—surveil-
lance, planning, financing. WHO Report 2007. Geneva: World Health
Organization; 2007. Report No. WHO/HTM/TB/2007.376. Available: http://
www.who.int/tb/publications/global_report/2007/en/index.html. Accessed 2
August 2007.
10. Hosseinipour MC, Neuhann FH, Kanyama CC, Namarika DC, Weigel R, et
al. (2006) Lessons learned from a paying antiretroviral therapy service in
the public health sector at kamuzu central hospital, Malawi: 1-year
experience. J Int Assoc Physicians AIDS Care 5: 103–108.
11. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-
up of antiretroviral therapy at primary care sites in Zambia: feasibility and
early outcomes. JAMA 296: 782–793.
12. Kwong-Leung Yu J, Chih-Cheng Chen S, Wang K, Chang C, Makombe S, et
al. (2007) True outcomes for patients on antiretroviral therapy who are
‘‘lost to follow-up’’ in Malawi. Bull World Health Organ 85: 550–554.
13. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, et al. (2006)
Adherence to HAART: a systematic review of developed and developing
nation patient-reported barriers and facilitators. PLoS Medicine 3: e438.
doi:10.1371/journal.pmed.0030438
14. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to
antiretroviral adherence for patients living with HIV infection and AIDS in
Botswana. J Acquir Immune Defic Syndr 34: 281–288.
15. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007)
Hunger, waiting time and transport costs: time to confront challenges to
ART adherence in Africa. AIDS Care 19: 658–665.
16. Egger M, MayM, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis
of HIV-1-infected patients starting highly active antiretroviral therapy: a
collaborative analysis of prospective studies. Lancet 360: 119–129.
17. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, et al. (2001) Rates of disease
progression by baseline CD4 cell count and viral load after initiating triple-
drug therapy. JAMA 286: 2568–2577.
18. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006)
Determinants of mortality and nondeath losses from an antiretroviral
treatment service in South Africa: implications for program evaluation.
Clin Infect Dis 43: 770–776.
19. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R (2005) Early mortality
among adults accessing a community-based antiretroviral service in South
Africa: implications for programme design. AIDS 19: 2141–2148.
20. Lawn SD, Wood R (2006) How can earlier entry of patients into
antiretroviral programs in low-income countries be promoted? Clin Infect
Dis 42: 431–432.
21. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, et al. (2005) Initial
response to highly active antiretroviral therapy in HIV-1C-infected adults
in a public sector treatment program in Botswana. J Acquir Immune Defic
Syndr 40: 336–343.
22. Bisson G, Ndwapi N, Rollins C, Avalos A, Gross R, et al. (2007) High rates of
death among patients lost to follow-up in Botswana’s national ART
program: implications for monitoring and evaluation [abstract]. 14th
Conference on Retroviruses and Opportunistic Infections (CROI); 2007
25–28 February; Los Angeles, California. Abstract 537. Available: http://
www.retroconference.org/2007/Abstracts/28788.htm. Accessed 27 July 2007.
23. Bisson GP, Frank I, Gross R, Lo Re V 3rd, Strom JB, et al. (2006) Out-of-
pocket costs of HAART limit HIV treatment responses in Botswana’s
private sector. AIDS 20: 1333–1336.
24. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, et al. (2005)
Antiretroviral therapy in public and private routine health care clinics in
Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin
Infect Dis 41: 108–111.
25. Guiard-Schmid JB, Montagut B, Ribadeau-Dumas F, EdooEdoo G, Makong
S, et al. (2004) TRICAM: Medico-economic pilot study on HAART for HIV-
infected patients in a private company of Cameroon [abstract]. XVth
International AIDS Conference; 2004 11–16 July; Bangkok, Thailand.
Abstract MoOrD1024.
26. Mosoko JJ, Akam W, Weidle PJ, Brooks J, Aweh A, et al. (2007) Survival and
adherence to ART in an era of decreasing drug cost in Limbe, Cameroon
[abstract]. 14th Conference on Retroviruses and Opportunistic Infections
(CROI); 2007 25–28 February; Los Angeles, California. Abstract 536.
Available: http://www.retroconference.org/2007/Abstracts/28199.htm. Ac-
cessed 27 July 2007.
27. Kenfak A, Tsague L, Koulla-Shiro S, Tejioken M, Kouanfack C, et al. (2007)
Challenges in assessing adherence to antiretroviral treatment in low
resources settings and impacts on national antiretroviral policy: results of a
retrospective multicentric cohort study in Cameroon [abstract]. XVIth
International AIDS Conference; August 14–18, 2006; Toronto, Canada.
Abstract CDB0765.
28. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, et al. (2003)
Virologic and immunologic outcomes and programmatic challenges of an
antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS 17:
S5–15.
29. Macharia DK, Chang LW, Lule G, Owili DM, Tesfaledet G, et al. (2003)
Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of
the experience of five physicians. AIDS 17: 938–940.
30. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006)
PLoS Medicine | www.plosmedicine.org October 2007 | Volume 4 | Issue 10 | e2981699
Retention of ART Patients in Africa
Viability and effectiveness of large-scale HIV treatment initiatives in sub-
Saharan Africa: experience from western Kenya. AIDS 20: 41–48.
31. Carillo de Casas E, Cox H, Ferreyra C, Isaakidis P, Mansilla C, San Miguel
MJ, et al. (2006) Gender differences in a large-scale HAART program in
western Kenya. XVIth International AIDS Conference; 2006 14–18 August;
Toronto, Canada. Abstract WEPE0243. Available: http://www.iasociety.org/
Default.aspx?pageId¼11&abstractId¼2192736. Accessed 27 July 2007.
32. Marston B, Macharia DK, Ng’ang’a L, Wangai M, Ilako F, et al. (2007) A
program to provide antiretroviral therapy to residents of an urban slum in
Nairobi, Kenya. JIAPAC 6: 106–112.
33. Karcher H, Omondi A, Odera J, Kunz A, Harms G (2007) Risk factors for
treatment denial and loss to follow-up in an antiretroviral treatment
cohort in Kenya. Trop Med Int Health 12: 687–694.
34. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R (2007)
Antiretroviral durability and tolerability in HIV-infected adults living in
urban Kenya. J Acquir Immune Defic Syndr 45: 304–310.
35. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006)
Scaling up of highly active antiretroviral therapy in a rural district of
Malawi: an effectiveness assessment. Lancet 367: 1335–1342.
36. Libamba E, Makombe S, Mhango E, de Ascurra TO, Limbambala E, et al.
(2006) Supervision, monitoring and evaluation of nationwide scale-up of
antiretroviral therapy in Malawi. Bull World Health Organ 84: 320–326.
37. Hosseinipour MC, Kanyama CC, Nkhalamba T, Phiri SJ, Weigel R, et al. (2006)
Safety and efficacy of D4T/3TC/NVP among HIV positive adults in Lilongwe,
Malawi [abstract]. XVth International AIDS Conference; 2004 11–16 July,
2004; Bangkok, Thailand. Abstract TuPeB4522. Available: http://gateway.nlm.
nih.gov/MeetingAbstracts/102282344.html. Accessed 27 July 2007.
38. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, et al. (2007)
Community support is associated with better antiretroviral treatment
outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop
Med Hyg 101: 79–84.
39. Palombi L, Narciso P, Perno CF, Mancinelli S, Guidotti G, et al. (2004) One
year of HAART in Mozambique: survival, virological, and immunological
results of DREAM Project in adults and children [abstract]. 11th Confer-
ence on Retroviruses and Opportunistic Infections; 2004 8–11 February;
San Francisco, California. Abstract 148. Available: http://www.
retroconference.org/2004/cd/Abstract/148.htm. Accessed: 27 July 2007.
40. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006)
Mortality and causes of death in adults receiving highly active antiretroviral
therapy in Senegal: a 7-year cohort study. AIDS 20: 1181–1189.
41. Bekker LG, Myer L, Orrell C, Lawn S, Wood R (2006) Rapid scale-up of a
community-based HIV treatment service: programme performance over 3
consecutive years in Guguletu, South Africa. S Afr Med J 96: 315–320.
42. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, et al.
(2007) Evaluation of a workplace HIV treatment programme in South
Africa. AIDS 21: S73–S78.
43. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004)
Outcomes after two years of providing antiretroviral treatment in
Khayelitsha, South Africa. AIDS 18: 887–895.
44. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence
to highly active antiretroviral therapy assessed by pharmacy claims predicts
survival in HIV-infected South African adults. J Acquir Immune Defic
Syndr 43: 78–84.
45. Ford N, Reuter H, Bedelu M, Schneider H, Reuter H (2006) Sustainability of
long-term treatment in a rural district: the Lusikisiki model of decentral-
ised HIV/AIDS care. Southern Afr J HIV Med Dec 2006: 17–22.
46. Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, et al. (2005)
Long-term experience providing antiretroviral drugs in a fee-for-service
HIV clinic in Uganda: evidence of extended virologic and CD4þ cell count
responses. J Acquir Immune Defic Syndr 38: 578–583.
47. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, et al. (2002)
Assessment of a pilot antiretroviral drug therapy programme in Uganda:
patients’ response, survival, and drug resistance. Lancet 360: 34–40.
48. Rigon A, Nattabi B, Pido B, Pierotti C, Ojom L, et al. (2006) Evaluation of
treatment outcomes and adherence among patients receiving antiretro-
viral therapy in the conflict-affected region of north Uganda [abstract].
XVIth International AIDS Conference; 2006 14–18 August; Toronto,
Canada. Abstract WEPE0131.
49. Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, et al. (2006)
Implementation of an Antiretroviral Access Program for HIV-1-Infected
Individuals in Resource-Limited Settings: Clinical Results From 4 African
Countries. J Acquir Immune 44: 262–267.
50. El-Sadr W, Elul B, Rabkin M, Hawken M, Lima J, et al. (2006) Rapid
expansion of HIV/AIDS care and treatment programs in 6 Sub-Saharan
countries [abstract]. XVIth International AIDS Conference; 2006 14–18
August; Toronto, Canada. Abstract CDB1122.
PLoS Medicine | www.plosmedicine.org October 2007 | Volume 4 | Issue 10 | e2981700
Retention of ART Patients in Africa
Editors’ Summary
Background. About 25 million people in sub-Saharan Africa are infected
with the human immunodeficiency virus (HIV), the cause of acquired
immunodeficiency syndrome (AIDS). Every year, about three million
more people become infected with HIV and 2 million die from AIDS in
this region, where the pandemic has reduced life expectancy, orphaned
many children, and reversed economic growth. Since 1996, HIV-positive
people living in wealthier parts of the world have had access to cocktails
of antiretroviral drugs that hold HIV in check and allow them to live
relatively normal, healthy lives. But these drugs are expensive and it is
only in the past five years that antiretroviral therapy (ART) programs have
been initiated in sub-Saharan Africa, often with international support.
Why Was This Study Done? For ART to work, HIV-infected individuals
whose immune systems have been damaged by the virus have to take
antiretroviral drugs regularly for the rest of their lives. If people take ART
irregularly or stop taking their medications they may become sicker or
die, or the viruses they carry may become resistant to antiretroviral
drugs. Several studies have looked at how well patients on ART stick to
their day-to-day medication schedules, but how long patients stay in
treatment programs, which they must do to prevent illness and death
from AIDS, has received little attention. In this study the researchers
reviewed reports of whether patients stay in treatment in ART programs
in sub-Saharan Africa, and also looked at the reasons why they drop out.
What Did the Researchers Do and Find? The researchers identified 32
scientific reports published or presented at meetings between 2000 and
2007 that gave details of the proportion of adult patients retained (alive
and receiving ART) in ART treatment programs (not including research
studies) in 13 countries in sub-Saharan Africa. The average follow-up
time of the programs (adjusted for number of patients in each) was 9.9
months. At this time, 77.5% of the patients were retained on average. Of
the patients not retained, just under half had died and half had been lost
to follow up. That is, they had missed clinic visits or had not picked up
their medication. Estimated average retention rates at 6, 12, and 24
months were 79.08%, 75% and 61.6%, respectively; retention rates
reported at 24 months ranged between 46% and 85% of patients. Finally,
using sensitivity analysis (a technique that can estimate best- and worst-
case possibilities), the researchers estimated that actual retention in ART
programs after 2 years probably lies between one-quarter and three-
quarters of patients.
What Do These Findings Mean? These results show that roughly half of
people starting HIV treatment programs in Africa are no longer receiving
treatment after two years. The overall success rates of African treatment
programs may actually be even lower, if one takes into account that
programs with very low retention may be unlikely to publish their
results. This study therefore indicates that a worrying number of patients
in sub-Saharan Africa who need ART are lost from treatment programs.
Because many of these patients are lost because they die from AIDS, one
way to improve retention might be to start treating people with ART
earlier, before they become seriously ill from HIV. Better efforts to find
out exactly why patients drop out of programs (for example, the cost of
drugs and/or of transport to clinics) might reduce the number of patients
lost to follow up. The researchers also suggest that ART programs with
very high retention rates might serve as models to improve retention
rates in other programs.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040298.
 Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
 HIV InSite is a regional page on sub-Saharan Africa from the University
of California, San Francisco
 Information is provided by the US Centers for Disease Control and
Prevention on the US President’s Emergency Plan for AIDS Relief in
various countries and regions
 Avert is an international AIDS charity that provides information on HIV
and AIDS in Africa
 Aidsmap is an international AIDS organization that summarizes
research about HIV/AIDS and reports news (in English, Spanish,
Portuguese, French, and Russian)
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